- 更多网络例句与类中风性的相关的网络例句 [注：此内容来源于网络，仅供参考]
-
Numeration data between the groups using chi-square test.Results:Clinical research:(1) Baseline data: Except for gastrointestinal sthenia syndrome andyin/yang syndrome, the two groups of patients in terms of gender, age, smoking,alcohol consumption, medical history, diseased region, NIHSS score, strokeTCM symptom integration and Gelashige Coma Scale score, as compared withno statistical difference (P＞0.05);(2) After treatment: Compared with pretherapy, the NIHSS score and strokeTCM symptom integration of two groups were prominently improved at 14±3days and 21±3 days. But the improvement of stroke TCM symptom integrationof TFXSJN group was superior to that of the control group, the difference wasstatistically significant (P＜0.05);(3) At 21±3 days, TFXSJN group\' s BI Index, SS-QOL score were higher,and NIHSS score were significantly lower than that of control group, withsignificant differences (P＜0.05); There were no significant differencebetween two groups\' score of mRS at 21±3 days (P＞0.05);(4) Adverse reactions:All patients in the two groups during the treatmenthad no adverse reaction.
结果：临床研究：(1)基线资料中，除腑实证及阴阳类证外，两组患者在性别、年龄、吸烟、饮酒、既往病史、病变部位、NIHSS评分、中风中医症征积分及哥拉斯哥昏迷量表评分等方面相比无统计学差异，具有可比性(P＞0.05)；(2)治疗后，两组患者在14±3天，21±3天时的NIHSS评分、中风中医症征积分较治疗前均有所改善(P＜0.05或P＜0.01)，但TFXSJN组患者的中风中医症征改善优于对照组，具有统计学意义P＜0.05(来源：Ae7B9c9cC论文网www.abclunwen.com；(3)21±3天时TFXSJN组患者的BI指数、SS-QOL评分均高于对照组，NIHSS评分明显低于对照组，差异具有显著性(P＜0.05)；21±3天两组的mRS评分无明显差异(P＞0.05)；(4)不良反应：两组患者在治疗期间均未出现明显不良反应。
- 更多网络解释与类中风性的相关的网络解释 [注：此内容来源于网络，仅供参考]
-
cerebral apoplexy：脑中风
发明中所治疗和预防的帕金森病(Parkinson's Disease)相关疾病及与一氧化氮有关的神经退行性疾病主要包括脑中风(Cerebral Apoplexy)、亨廷顿式病(Hun[A21833-0027-0001] 四环素类药防治帕金森及一氧化氮有关的神经退行性疾病 [摘要] 本发明提供了一种全新的方法,
-
apoplectoid：类中风性的
apoplectigenous | 引起中风的 | apoplectoid | 类中风性的 | apoplexy | 中风